title: Soluble angiogenic factors: implications for chronic myeloproliferative disorders.
abstract: The role of angiogenesis for the progressive growth and metastatic process of tumours is well established. What is not clear, though, is the clinical prognostic significance of the angiogenic factors in malignant haematological diseases. In this study, we have assessed the plasma and serum levels of two major angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) in 55 patients affected by chronic myeloproliferative disorders (CMD). This series included 25 patients with essential thrombocythemia (ET), 10 patients with chronic myelocytic leukaemia (CML), 14 patients with polycythemia vera (PV), and 6 patients with primary myelofibrosis (MF), and they were compared to 20 healthy control subjects. In all patients the plasma VEGF concentration was significantly increased to the healthy control group (P < 0.004). The highest concentrations were found in the patients with ET (178.25 +/- 125.22 pg/ml). The VEGF levels were significantly higher in CMD patients with vascular complications than those in CMD patients without complications (P < 0.01). The b-FGF serum levels also appeared to be significantly higher in almost all the CMD patients compared to the control group (P < 0.07). A significant correlation was found between the VEGF levels and the platelet count in the ET patients and the spleen index in the CML patients. VEGF level, in this study, is associated with increased risk of thrombotic complications. There is evidence of increased levels of soluble angiogenic factors in malignant haematological disorders, but their contribution to the progression of diseases is yet unclear.
authors.affiliation: Division of Hematology, University of Messina, Italy. camilla.si@tiscalinet.it
authors.forename: C
authors.initials: C
authors.lastname: Musolino
authors.forename: L
authors.initials: L
authors.lastname: Calabro'
authors.forename: G
authors.initials: G
authors.lastname: Bellomo
authors.forename: F
authors.initials: F
authors.lastname: Martello
authors.forename: B
authors.initials: B
authors.lastname: Loteta
authors.forename: C
authors.initials: C
authors.lastname: Pezzano
authors.forename: V
authors.initials: V
authors.lastname: Rizzo
authors.forename: A
authors.initials: A
authors.lastname: Alonci
mesh_terms: D016022:Case-Control Studies; D002908:Chronic Disease; D016228:Endothelial Growth Factors / Q000097:blood*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000150:complications / Q000209:etiology; D012995:Solubility; D013927:Thrombosis / Q000097:blood / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2